WBB Securities analyst Stephen Brozak reiterated a Buy rating on T2 Biosystems (TTOO) today. The company’s shares closed yesterday at $3.14, close to its 52-week low of $2.94.
Brozak observed:
“We are therefore reiterating our Strong Buy Rating and continuing our 12-month Price Target of $20.00.”
According to TipRanks.com, Brozak is a 4-star analyst with an average return of 12.6% and a 47.4% success rate. Brozak covers the Healthcare sector, focusing on stocks such as RedHill Biopharma, ADMA Biologics, and Motif Bio plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for T2 Biosystems with a $10 average price target, representing a 218.5% upside. In a report issued on February 27, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $11 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.98 and a one-year low of $2.94. Currently, T2 Biosystems has an average volume of 506.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection including one colony forming unit per milliliter. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
